Q-omics provides the consensus-scored CYP4F11 profile across patient tissues and cancer cell-line models. CYP4F11 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CYP4F11 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, CYP4F11 protein abundance shows 13,503 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where CYP4F11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP4F11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP4F11 survival associations across molecular data types. CYP4F11 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP4F11 RNA expression–survival associations across cancer types. High CYP4F11 expression shows unfavorable associations in HNSC and LGG, but favorable associations in BRCA, MESO, STAD and ACC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for CYP4F11 RNA expression.
This table summarizes CYP4F11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CYP4F11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP4F11 shows lower tumor expression in CHOL and higher tumor expression in HNSC, LUAD, LUSC, KIRP and UCEC. The HNSC box plot shows higher CYP4F11 RNA expression in tumor versus normal tissue (log2 FC = +1.507, t-test p < 0.001).
This table shows molecular features associated with CYP4F11 in patient tissues and cancer cell lines. In patient samples, CYP4F11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP4F11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and OVARY.
